Rizatriptan

Rizatriptan
Klinički podaci
Prodajno ime	Maxalt, Maxalt MLT, Maxalt-MLT
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	2-3 h
Identifikatori
CAS broj	145202-66-0
ATC kod	N02CC04 (WHO)
PubChem	CID 5078
IUPHAR/BPS	51
DrugBank	DB00953
ChemSpider	4900
ChEBI	CHEBI:48273
ChEMBL	CHEMBL905
Hemijski podaci
Formula	C15H19N5
Molarna masa	269,345
	SMILES CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2; ;
	InChI InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 ; Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	178—180 °C (352—356 °F)

Rizatriptan je organsko jedinjenje, koje sadrži 15 atoma ugljenika i ima molekulsku masu od 269,345 Da.^[1]^[2]^[3]^[4]^[5]^[6]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	1
Broj rotacionih veza	5
Particioni koeficijent^[7] (ALogP)	2,1
Rastvorljivost^[8] (logS, log(mol/L))	-3,7
Polarna površina^[9] (PSA, Å²)	49,7

Reference

^ Wellington K, Plosker GL (2002). „Rizatriptan: an update of its use in the management of migraine”. Drugs. 62 (10): 1539—74. PMID 12093318.
^ Wellington K, Jarvis B (2002). „Spotlight on rizatriptan in migraine”. CNS Drugs. 16 (10): 715—20. PMID 12269863.
^ Ikemoto, Fumihiko; Toru, Taro; Aijima, Hiroshi; Natsumeda, Yutaka (април 2004). „Rizatriptan (Maxalt®), a new entity of triptan for migraine: Pharmacology and therapeutic relevance”. Nippon Yakurigaku Zasshi. 123 (4): 295—302. PMID 15056946. doi:10.1254/fpj.123.295.
^ Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR. „An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy”. Proc West Pharmacol Soc. 2002 (45): 199—210. PMID 12434581.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Rizatriptan

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Wellington K, Plosker GL (2002). „Rizatriptan: an update of its use in the management of migraine”. Drugs. 62 (10): 1539—74. PMID 12093318.

[2] Wellington K, Jarvis B (2002). „Spotlight on rizatriptan in migraine”. CNS Drugs. 16 (10): 715—20. PMID 12269863.

[3] Ikemoto, Fumihiko; Toru, Taro; Aijima, Hiroshi; Natsumeda, Yutaka (април 2004). „Rizatriptan (Maxalt®), a new entity of triptan for migraine: Pharmacology and therapeutic relevance”. Nippon Yakurigaku Zasshi. 123 (4): 295—302. PMID 15056946. doi:10.1254/fpj.123.295.

[4] Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR. „An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy”. Proc West Pharmacol Soc. 2002 (45): 199—210. PMID 12434581.

[5] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[6] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[7] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[8] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[9] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]